Neuroscience

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders

Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’sROME, July 12, 2023 (GLOBE…

2 years ago

NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player

Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression TreatmentMALVERN, Pa., July 11, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:…

2 years ago

Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer

Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy ProgramsMIAMI, July 11, 2023 (GLOBE NEWSWIRE) -- Longeveron…

2 years ago

BrainsWay Accelerates International Expansion in India

Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™BURLINGTON, Mass. and JERUSALEM, July 11, 2023…

2 years ago

Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership

EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATIONSELECTED PROGRAMMES…

2 years ago

New Disease Modifying Drug for Alzheimer’s Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring

Vital breakthrough for Alzheimer's patients worldwide with Eisai's Leqembi FDA approval; Cognetivity Neurosciences' AI CognICA technology poised to play pivotal…

2 years ago

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Company to voluntarily delist from the Toronto Stock Exchange (TSX)Last trading day on TSX will be July 21, 2023 TORONTO, Ontario…

2 years ago

Advanced FDA Cleared Magstim Horizon 3.0 Transcranial Magnetic Stimulation Now Available in United Kingdom

Approval by UKCA Empowers UK Physicians to Advance Care of Treatment Resistant Depression, Obsessive Compulsive Disorder, and Anxious Depression with…

2 years ago

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

2 years ago

gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms

ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced…

2 years ago